HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis. TREMFYA ® is indicated for the treatment of adults with moderately to severely active ulcerative colitis.

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis By Johnson & Johnson ...

TREMFYA ® is a prescription medicine approved to treat adults with active PsA. In two medical studies, more than half of patients treated with TREMFYA ® had at least a 20 percent improvement in ...

News PR Newswire New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis ...

IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including active psoriatic arthritis. 2,3,4,5,6 ...